Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Known prostate cancer with a clinical concern for the presence of metastatic disease as delineated below:~   * Treatment naïve patients with one of the following risk factors: CAPRA (Cancer of the Prostate Risk Assessment) score ≥ 5, Prostate-specific antigen (PSA) ≥ 15 ng/mL and/or Gleason score ≥ 4+4.~  * Patients with biochemical recurrence after prostatectomy or radiation therapy with a PSA doubling time less than 12 months.~     i. These patients may have received androgen deprivation therapy prior to imaging.~  * Patients with castrate resistant prostate cancer with progressive disease as defined by Prostate Cancer Clinical Trials Working Group (PCWG2) criteria (27).~     i. Patients with castrate resistant prostate cancer can be either on treatment or off treatment~2. Age \> 18.~3. Karnofsky performance status of \> 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent).~4. Ability to understand a written informed consent document, and the willingness to sign it.~Exclusion Criteria:~1. Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET scanner due to BMI.~2. Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.).~3. Inability to complete the needed investigational due to other reasons (severe claustrophobia, radiation phobia, etc.).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High-risk prostate cancer pre-prostatectomy (preRP) population (Type: EXPERIMENTAL): Patients with high-risk prostate cancer pre-prostatectomy.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
- Biochemical Recurrence (BCR) (Type: EXPERIMENTAL): Patients with prostate cancer with biochemical recurrence~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
- Castrate Resistant Prostate cancer (CRCP) population (Type: EXPERIMENTAL): Patients with castrate resistant prostate cancer.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.

Based on this trial design, predict the completion outcome and termination type (if applicable).